Rhumbline Advisers Has $59.98 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Rhumbline Advisers decreased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 448,852 shares of the life sciences company’s stock after selling 7,737 shares during the quarter. Rhumbline Advisers owned about 0.28% of Illumina worth $59,980,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of ILMN. Versant Capital Management Inc grew its position in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the period. Golden State Wealth Management LLC acquired a new stake in shares of Illumina during the 4th quarter worth approximately $32,000. TD Private Client Wealth LLC grew its position in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after buying an additional 141 shares during the period. V Square Quantitative Management LLC grew its position in shares of Illumina by 50.6% during the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock worth $52,000 after buying an additional 132 shares during the period. Finally, Private Trust Co. NA grew its position in Illumina by 81.2% in the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after purchasing an additional 212 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Down 1.5 %

ILMN stock opened at $100.24 on Monday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $15.90 billion, a PE ratio of -13.05 and a beta of 1.10. Illumina, Inc. has a twelve month low of $99.35 and a twelve month high of $156.66. The stock has a 50-day simple moving average of $132.74 and a two-hundred day simple moving average of $134.82.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. On average, equities analysts predict that Illumina, Inc. will post 4.42 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on ILMN shares. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and reduced their price target for the company from $190.00 to $165.00 in a research report on Wednesday, December 11th. Royal Bank of Canada cut their price objective on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Robert W. Baird lifted their price objective on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. JPMorgan Chase & Co. lifted their target price on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, Canaccord Genuity Group lowered their target price on Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Illumina currently has a consensus rating of “Moderate Buy” and an average price target of $159.45.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.